Achillion Pharmaceuticals

INVESTORS

Committee Composition

  Audit Committee Compensation Committee Nominating Committee Strategy Committee Compliance Committee
David I. Scheer
David I. Scheer
Chairman of the Board

David Scheer was involved in the founding of Achillion and currently serves as its Chairman of the Board, Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee and the Strategy and Corporate Development Committee. He is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences.

  Member of the Compensation Committee Chair of the Nominating Committee Member of the Strategy Committee Chair of the Compliance Committee
Jason S. Fisherman MD
Jason S. Fisherman MD
Director

Dr. Fisherman is Managing Director of Synthesis Capital, formerly Advent Healthcare Ventures, a life science venture capital firm, where he specialized in biotechnology and emerging pharmaceutical investments. He has served as a director of Achillion since March 2000.

Member of the Audit Committee   Member of the Nominating Committee Member of the Strategy Committee  
Gary E. Frashier
Gary E. Frashier
Director

Mr. Frashier joined Achillion's Board of Directors in March 2008. Formerly holding Chief Executive and/or Chairman roles at OSI Pharmaceuticals, Millipore Corporation, Merrimack Pharmaceuticals and eXeGenex, and currently is President of Management Associates, a life sciences consulting firm.

Member of the Audit Committee Member of the Compensation Committee      
Kurt Graves
Kurt Graves
Director

Mr. Graves joined Achillion's Board of Directors in June 2012. Mr. Graves is Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc. Prior to Intarcia, he held senior management roles at Merck, Novartis and Vertex Pharmaceuticals.

  Member of the Compensation Committee   Chair of the Strategy Committee  
Michael D. Kishbauch
Michael D. Kishbauch
Director

Mr. Kishbauch was Achillion's President and Chief Executive Officer from July 2004 through May 2013. 

        Member of the Compliance Committee
Robert L. Van Nostrand
Robert L. Van Nostrand
Director

Mr. Van Nostrand has served as a member of Achillion's Board of Directors since April 2007. Mr. Van Nostrand formerly served as the Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc, and as Chief Financial Officer of both AGI Dermatics and OSI Pharmaceuticals, where he also served as Chief Compliance Officer.

 

Chair of the Audit Committee       Member of the Compliance Committee
Frank Verwiel MD
Frank Verwiel MD
Director

Dr. Verwiel joined Achillion’s Board of Directors in December 2016. Prior to its acquisition in 2014 by Forest Laboratories, Dr. Verwiel served as President, Chief Executive Officer and Board member at Aptalis Pharma. Prior to Aptalis, he held international senior management positions with Merck & Co. Inc. and at Servier.

Member of the Audit Committee Chair of the Compensation Committee   Member of the Strategy Committee  
Nicole Vitullo
Nicole Vitullo
Director

Ms. Vitullo joined Achillion's Board of Directors in September 2010. Ms. Vitullo is a partner with Domain Associates LLC, a venture capital firm with an exclusive focus on life sciences.

 

    Member of the Nominating Committee   Member of the Compliance Committee
= Chair = Member